chronic constipation

Prucalopride (R-93877) is a selective, high-affinity 5-HT4A/4B receptor agonist (Ki: 2.5/8 nM). It has >290-fold selectivity for 5-HT4A/4B receptor than other 5-HT receptor subtypes.

Elobixibat (A 3309) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.

Linaclotide, developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, is a potent and selective guanylate cyclase C agonist.

Linaclotide acetate is used as an oral guanylate cyclase C agonist linaclotide; 14 amino acid peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation.

TD-2749 is a selective 5-HT4 agonist discovered by Theravance through multivalent compound design as part of a compound discovery project aimed at finding new treatments for gastrointestinal motility disorders. It is primarily used to treat chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia, and diabetic gastroparesis.

5-HT4R agonist-2 (Compound 4) is a selective 5-HT4 receptor agonist with an EC50 of 0.41 nM. This compound significantly enhances intestinal and colonic transit, increases stool output and moisture content, while maintaining minimal systemic absorption, making it a promising candidate for research in chronic idiopathic constipation.

Relenopride, a 5-HT agonist, is used potentially for the treatment of chronic constipation.

Bisoxatin (LA 271A) is an oral laxative that can be used to study contact laxatives for chronic constipation.

Velusetrag(TD-5108)is an effective, selective, and highly potent agonist of the 5-HT4 receptor, and being developed for the treatment of gastroparesis, chronic constipation, and irritable bowel syndrome.

Lubiprostone (RU-0211), an activator of ClC-2 chloride channels, is used in the therapy of idiopathic chronic constipation.

Elobixibat hydrate, a potent inhibitor of the ileal bile acid transporter (IBAT), exhibits IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human, mouse, and canine IBAT, respectively. It is utilized in the research of chronic idiopathic constipation (CIC).

Lubiprostone (hemiketal) (RU-0211 (hemiketal)), a selective activator of the chloride channel 2 (CLCN2), facilitates the treatment of chronic idiopathic constipation and opioid-induced constipation. It functions by enhancing CLCN2 channel activity, which boosts chloride ion secretion in the intestines, subsequently increasing fluid secretion and improving intestinal peristalsis. Additionally, Lubiprostone (hemiketal) may be utilized in research related to chronic constipation and cancer.

Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

Elobixibat-D5 is a deuterated compound of Elobixibat. Elobixibat (T15209) has a CAS number of 439087-18-0. Elobixibat (T15209) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat (T15209) can be used in studies about chronic idiopathic constipation.